[1] |
Nygaard B, Hegedüs L, Gervil M, et al. Influence of compensated radioiodine therapy on thyroidvolume and incidence of hypothyroidism in Graves′disease[J]. J Intern Med, 1995, 238(6):491-497.
|
[2] |
Farkasova T, Gurska S, Witkovsky V, et al. Significance of amino acid substitution variants of DNA repair genes in radiosusceptibility of cervical cancer patients; a pilot study[J]. Neoplasma, 2008, 55(4):330-337.
|
[3] |
Wang H, Zhu L, Gao J, et al. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells[J]. Oncol Rep, 2015, 33(1):403-412.
|
[4] |
Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor:mechanisms of activation and signalling[J]. Exp Cell Res, 2003, 284(1):31-53. doi: 10.1016/S0014-4827(02)00098-8
|
[5] |
Toulany M, Kasten-Pisula U, Brammer I, et al. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair[J]. Clin Cancer Res, 2006, 12(13):4119-4126. doi: 10.1158/1078-0432.CCR-05-2454
|
[6] |
Meijer TW, Kaanders JH, Span PN, et al. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy[J]. Clin Cancer Res, 2012, 18(20):5585-5594. doi: 10.1158/1078-0432.CCR-12-0858
|
[7] |
中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志, 2007, 46(10):876-882. doi: 10.3760/j.issn:0578-1426.2007.10.035
|
[8] |
Asami K, Atagi S. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer[J]. World J Clin Oncol, 2014, 5(4):646-659. doi: 10.5306/wjco.v5.i4.646
|
[9] |
Marti U, Ruchti C, Kämpf J, et al. Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues[J]. Thyroid, 2001, 11(2):137-145. doi: 10.1089/105072501300042785
|
[10] |
Bussink J, van der Kogel AJ, kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer[J]. Lancet Oncol, 2008, 9(3):288-296. doi: 10.1016/S1470-2045(08)70073-1
|
[11] |
Nijkamp MM, Span PN, Terhaard CH, et al. Epidermal growth factor receptor expression in laryngeal cancer predicts the effect of hypoxia modification as an additive to accelerated radiotherapy in a randomised controlled trial[J]. Eur J Cancer, 2013, 49(15):3202-3209. doi: 10.1016/j.ejca.2013.06.024
|
[12] |
Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma[J]. Cancer Res, 2002, 62(24):7350-7356.
|
[13] |
Maurizi M, Almadori G, Ferrandina G, et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma[J]. Br J Cancer, 1996, 74(8):1253-1257. doi: 10.1038/bjc.1996.525
|
[14] |
Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas:inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis[J]. Clin Cancer Res, 2000, 6(6):2166-2174.
|
[15] |
Chiovato L, Fiore E, Vitti P, et al. Outcome of thyroid function in Graves′ patients treated with radioiodine:role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage[J]. J Clin Endocrinol Metab, 1998, 83(1):40-46.
|
[16] |
谭建, 王澎, 张丽娟, 等. 131I治疗Graves病后早发甲低相关因素的综合分析[J].中华核医学杂志, 2005, 25(6):325-328. doi: 10.3760/cma.j.issn.2095-2848.2005.06.001
|
[17] |
Zanotti-Fregonara P, Hindié E. On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer[J]. Eur J Nucl Med Mol Imaging, 2010, 37(12):2264-2266. doi: 10.1007/s00259-010-1608-9
|
[18] |
Erem C, Kandemir N, Hacihasanoglu A, et al. Radioiodine treatment of hyperthyroidism:prognostic factors affecting outcome[J]. Endocrine, 2004, 25(1):55-60.
|